GlassScriptPhysician profile
Ryan T Koch
NPI 1770092967
$4,709.30
in general payments reported to CMS, 2019-2025
19 companies · $981 in 2025
The $981 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $589 · 2022: $815 · 2023: $1,058 · 2024: $1,267 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,305.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,327.16 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Abbott Laboratories | $608.30 | 2021-2025 | Navitor, Dragonfly Opstar, Mitraclip |
| Astrazeneca Pharmaceuticals LP | $593.62 | 2021-2024 | Farxiga, Lokelma |
| Edwards Lifesciences Corporation | $551.16 | 2021-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Atricure, INC. | $409.84 | 2023-2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Isolator Surgical Ablation System |
| Shockwave Medical, INC | $257.09 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $221.31 | 2021-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $159.96 | 2021-2024 | Xarelto |
| Abiomed | $139.08 | 2025 | |
| Boston Scientific Corporation | $110.64 | 2022-2025 | Epic Vascular, Eluvia |
| Chiesi USA, INC. | $63.08 | 2022-2023 | Kengreal, Cleviprex |
| Merck Sharp & Dohme LLC | $49.83 | 2023-2024 | Keytruda, Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $46.44 | 2025 | |
| Pfizer INC. | $41.29 | 2023-2024 | |
| Acist Medical Systems, INC. | $35.95 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.62 | 2025 | Jardiance |
| Shionogi INC | $26.25 | 2023 | Fetroja |
| Terumo Medical Corporation | $23.39 | 2021 | |
| Amgen INC. | $18.29 | 2023 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Koch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.